Protective effect of 6-MFA, an interferon inducer and antiviral agent of fungal origin, was investigated against the neurotoxic effects induced by acrylamide in rats. Animals of 6-MFA (2.5, 5, 10 mg/100 gm, i.p.) pretreated plus acrylamide (ACR) group exhibited a reduction in development of hind limb paralysis which was 34, 25 and 20 (%) with increasing doses of 6-MFA respectively. Corpus striatal dopamine binding was significantly raised in the ACR treated rats while 6-MFA (10 mg) plus ACR group showed no significant change, in comparison to respective controls. Increased binding in the 6-MFA (2.5, 5 mg) pretreated plus ACR group was also evident. Glutathione-s-transferase (GST) activity was markedly reduced (66%) in ACR alone rats while no change was noted in rats pretreated with either dose of 6-MFA alone. However, a significant reversal was noted in animals of 6-MFA plus ACR group in a dose related manner. Conservation of glutathione levels and involvement of microglia, gamma-interferon and other lymphokines has been suggested for the observed protective effect of 6-MFA against neurotoxicity of ACR.